Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that using Losartan would help decrease proteinuria in pediatric chronic kidney disease with tubular proteinuria.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Ministry of Food and Drug Safety, Korea
• Treatments: Losartan

Criteria

Inclusion Criteria:

• Age: 2years or older and younger than 18 years

• estimated GFR ≥ 30mL/min/m^2

• Mean urinary protein-creatinine ratio > 0.3 g/g from three first-morning spot urine collections

• Renal hypoplasia/dysplasia, Reflux nephropathy, Polycystic kidney disease, Lowe syndrome, Dent disease, Tubulointerstitial nephritis, Nephronophthisis/Medullary cystic disease, Obstructive uropathy(including PUV, UPJ obstruction, UVJ obstruction)

Exclusion Criteria:

• hypertension

• under dialysis or organ transplanted

• bilateral renal artery stenosis or primary hyperaldosteronism

• pregnant or nursing